Sanofi Pasteur says US FDA approves Daptacel vaccine for fifth consecutive dose

PARIS (Thomson Financial) - Sanofi Pasteur, the vaccines division of French pharmaceutical giant Sanofi-Aventis, said the US Food and Drug Administration has approved its Daptacel vaccine for use as the fifth consecutive dose in the series of childhood vaccinations against diptheria, tetanus and acellular pertussis.

Daptacel had already been approved for four consecutive doses administered at two, four, six and between 15 and 20 months of age. The new approval is for the fifth dose administered to children between the ages of four and six years old. [e-mail] gk1/ejp COPYRIGHT Copyright Thomson Financial News Limited 2007. All rights reserved. The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.